Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2021 | 2018 | 2017
Number of items: 5.

2021

Hartlapp, I., Valta-Seufzer, D., Siveke, J., Alguel, H., Goekkurt, E., Siegler, G. M., Martens, U. M., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., Boeck, S., Ettrich, T. J., Held, S., Keller, R., Anger, F., Germer, C-T., Stang, H. A., Heinemann, V. and Kunzmann, V. (2021). Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multi-agent induction chemotherapy: Results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113). Ann. Oncol., 32. S. S1091 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Rau, B., Lang, H., Konigsrainer, A., Gockel, I., Rau, H-G., Seeliger, H., Lerchenmuller, C., Reim, D., Wahba, R., Angele, M., Heeg, S., Keck, T., Weimann, A., Topp, S., Piso, P., Brandl, A., Trips, E., Heinemann, V. and Thuss-Patience, P. C. (2021). The effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastasis (PM): A randomized multicentre phase III trial (GASTRIPEC-I-trial). Ann. Oncol., 32. S. S1040 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

2018

Haas, M., Waldschmidt, D., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R. J. C., Malfertheiner, P., Illerhaus, G., Kubicka, S., Held, S., Westphalen, C. B., Kruger, S., Boeck, S. and Heinemann, V. (2018). Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT). Ann. Oncol., 29. S. 243 - 244. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Modest, D. P., Denecke, T., Pratschke, J., Ricard, I., Lang, H., Bemelmans, M., Becker, T., Rentsch, M., Seehofer, D., Bruns, C. J., Gebauer, B., Modest, H. I., Held, S., Folprecht, G., Heinemann, V. and Neumann, U. P. (2018). Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. Eur. J. Cancer, 88. S. 77 - 87. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

2017

Modest, D. P., Denecke, T., Pratschke, J., Lang, H., Bemelmans, M., Becker, T., Rentsch, M., Seehofer, D., Bruns, C. J., Gebauer, B., Stintzing, S., Modest, H. I., Held, S., Folprecht, G., Heinemann, V. and Neumann, U. P. (2017). Central evaluation for surgical treatment options in FIRE-3-updated results and impact on overall survival. Oncol. Res. Treat., 40. S. 122 - 123. BASEL: KARGER. ISSN 2296-5262

This list was generated on Wed Feb 1 05:04:58 2023 CET.